A bacteriostatic composition, a preparation method therefor and a use thereof are provided. The bacteriostatic composition includes one or more of a fatty acid and/or a salt thereof, one or more of a dicarboxylic acid and/or a salt thereof, one or more of an aromatic alcohol, and one or more of an aromatic acid and/or a salt thereof. The bacteriostatic composition may be made into an aqueous solution, a water-soluble gel, a foam, a spray, an ointment, a powder, a film, a capsule, a suppository, or a tablet, and may be used for inhibiting harmful microorganisms, particularly abnormal flora within the vagina.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

Disclosed is a suppository comprising a suppository base. The suppository may have a length, relative to a horizontal axis, that is greater than its width, relative to a vertical axis. The suppository may have a proximal end and a distal end along the horizontal axis. The proximal end may be adapted for insertion into a body cavity. The distal end may have at least one indentation and adapted to be gripped, e.g., during manual insertion of the suppository into the body cavity.

Disclosed is a suppository comprising a suppository base. The suppository may have a length, relative to a horizontal axis, that is greater than its width, relative to a vertical axis. The suppository may have a proximal end and a distal end along the horizontal axis. The proximal end may be adapted for insertion into a body cavity. The distal end may have at least one indentation and adapted to be gripped, e.g., during manual insertion of the suppository into the body cavity.

The invention relates to a personal care product for alleviating skin dryness, includes facial skin dryness, breast skin dryness and vulval dryness and for restoring vaginal flora, acidic pH in the vagina, and vaginal health. Embodiments of the personal care product include a formulation including at least about 83 wt. % plant-based glycerides; from about 0.05 wt. % to about 0.15 wt. % sodium hyaluronate; and from about 0.01 wt. % to about 1.5 wt. % sea buckthorn powder. Another embodiment includes a personal care product including at least 55 wt. % plant-based glycerides and from about 20 wt. % to about 42 wt. % sucrose. The personal care product may also include shea olein. The person care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial agent, and synthetic hormone.

The invention relates to a personal care product for alleviating skin dryness, includes facial skin dryness, breast skin dryness and vulval dryness and for restoring vaginal flora, acidic pH in the vagina, and vaginal health. Embodiments of the personal care product include a formulation including at least about 83 wt. % plant-based glycerides; from about 0.05 wt. % to about 0.15 wt. % sodium hyaluronate; and from about 0.01 wt. % to about 1.5 wt. % sea buckthorn powder. Another embodiment includes a personal care product including at least 55 wt. % plant-based glycerides and from about 20 wt. % to about 42 wt. % sucrose. The personal care product may also include shea olein. The person care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial agent, and synthetic hormone.

In one aspect, the disclosure relates to pharmaceutical compositions comprising 2′-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates to methods of treating hematological disorders and diseases associated with abnormal cell proliferation using the same. In a still further aspect, the disclosure relates to kits comprising 2′-deoxycytidine analogs useful for treating hematological disorders and diseases associated with abnormal cell proliferation. In still another aspect, the disclosure relates to methods for increasing fetal hemoglobin levels in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection. In an embodiment, this disclosure provides a particle heater comprising a carrier admixed with a material that interacts with an exogenous source; wherein the material absorbs and converts the energy from the exogenous source into heat, then the heat travels outside the particle heater to induce localized hyperthermia at a temperature sufficient to selectively kill unwanted cells, and further wherein the particle heater structure is constructed such that it passes the Extractable Cytotoxicity Test.

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.